

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. *N Engl J Med* 2005;352:2082-90.

Appendix A: High-risk conditions as defined by ICD-9-CM codes and prescription medications in Tennessee Medicaid data files.

High-risk Condition ^a	ICD-9-CM Codes	Condition-specific Prescription Medications ^a
Human Immunodeficiency Virus (HIV) infection^b	042.XX-044.XX; V08	zidovudine, didanosine, zalcitabine, stavudine, indinavir, ritonavir, saquinavir, nevirapine, lamivudine, nelfinavir, delavirdine, abacavir, amprenavir, efavirenz, lamivudine-zidovudine, abacavir-lamivudine-zidovudine, lopinavir-ritonavir, atazanavir
Sickle cell disease^b	282.6	
Nonasthma COPD^b	277.0; 770.7; 490.XX – 496.XX except 493.XX (asthma); 500.XX – 506.XX; 515.XX-517.XX; 519.9	

Cardiac disease, including congenital heart disease^b	393.XX-398.XX; 402.XX-404.XX; 410.XX-414.XX; 415.XX-417.XX; 425.XX; 428.XX; 429.XX; 745.XX- 746.XX; 747.1 – 747.4	digoxin
--	--	---------

<p>Cancer/ Immunosuppression, including transplant recipients and disorders of immune function ^b</p>	<p>140.XX-208.9 except 173.XX; 279.XX; V42.0; V42.1; V42.6; V42.7; V42.8; 996.XX</p>	<p>azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, sirolimus, daclizumab, oral corticosteroids (\geq 60 days in past year), filgrastim, sargramostim, and chemotherapeutic agents including alkylating agents (busulfan, chlorambucil, cyclophosphamide, mechlorethamine hydrochloride, mitomycin, cisplatin, carmustine, temozolomide), antimetabolites (mecaptopurine, fluorouracil, cytarabine, melphalan, thioguanine, etoposide, fludarabine phosphate, capecitabine, gemcitabine), antibiotics (bleomycin sulfate, doxorubicin hydrochloride, actinomycin, mitoxantrone hydrochloride, idarubicin hydrochloride), plant alkaloids (vincristine sulfate, vinblastine sulfate, paclitaxel, vinorelbine), anti-estrogens (tamoxifen citrate, toremifene citrate) and miscellaneous anti-neoplastic agents (protein-asparaginase-mannitol, hydroxyurea, procarbazine hydrochloride, lomustine, mitotane, testolactone, aminoglutethimide, interferon alpha, leuprolide acetate, flutamide, carboplatin, goserelin acetate, levamisole, estamustine phosphate sodium, interferon gamma-1B, altretamine, aldesleukin, bicalutamide, anastrozole, nilutamide, trimetrexate, letrozole, alitretinoin, irinotecan hydrochloride, bexarotene, tretinoin, imatinib, topotecan hydrochloride, arsenic trioxide, fulvestrant, gefitinib, rituximab)</p>
--	--	--

Chronic renal or hepatic disease, including cirrhosis^b	571.XX; 581.XX- 583.XX; 585.XX- 587.XX	
Chronic oral corticosteroid use		triamcinolone, fludrocortisone, methylprednisolone, prednisolone, prednisone, paramethasone, cortisone acetate, dexamethasone, hydrocortisone, and celestone
Diabetes mellitus^b	250.XX	insulin, oral hypoglycemics (chlorpropamide, tolazamide, tolbutamide, acetohexamide, glyburide, glipizide, metformin, acarbose, glimepiride, troglitazone, repaglinide, miglitol, maleate, pioglitazone, nateglinide, glyburide-metformin, rosiglitazone-metformin, metformin-glipizide)
Alcohol Abuse	303.XX; 305.0; 305.01; 291.1; 291.2; V11.3	
Tobacco Use	305.1; V15.82	

^a From claims in the year prior to the index date; ^b Condition must be found for one hospital or emergency department discharge or two outpatient visits of different date; ^cTotal ≥120 days supply in past year